ATE526018T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents

Verbindungen zur behandlung von stoffwechselstörungen

Info

Publication number: ATE526018T1
Authority: AT; Austria
Prior art keywords: carbon atoms; ring; alkyl; hydrogen; treatment
Prior art date: 2003-04-30

Application number

AT04750363T

Other languages

English (en)

Inventor

Kirvin Hodge

Shalini Sharma

Borstel Reid Von

Original Assignee

Wellstat Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-30

Filing date

2004-04-20

Publication date

2011-10-15

2004-04-20 Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526018T1 publication Critical patent/ATE526018T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
208000030159 metabolic disease Diseases 0.000 title abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 7
125000000217 alkyl group Chemical group 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
208000010706 fatty liver disease Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
-1 perfluoromethoxy Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT04750363T 2003-04-30 2004-04-20 Verbindungen zur behandlung von stoffwechselstörungen ATE526018T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46666303P	2003-04-30	2003-04-30
PCT/US2004/012141 WO2004098496A2 (en)	2003-04-30	2004-04-20	Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number	Publication Date
ATE526018T1 true ATE526018T1 (de)	2011-10-15

Family

ID=33434973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04750363T ATE526018T1 (de)	2003-04-30	2004-04-20	Verbindungen zur behandlung von stoffwechselstörungen

Country Status (12)

Country	Link
US (2)	US7442796B2 (de)
EP (1)	EP1617835B1 (de)
JP (1)	JP4837557B2 (de)
KR (1)	KR101192272B1 (de)
CN (1)	CN100348186C (de)
AT (1)	ATE526018T1 (de)
AU (1)	AU2004237602B2 (de)
CA (1)	CA2522738C (de)
IL (1)	IL171638A (de)
MX (1)	MXPA05011592A (de)
NZ (1)	NZ543789A (de)
WO (1)	WO2004098496A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100965201B1 (ko) *	2001-06-12	2010-06-24	웰스테트 테라퓨틱스 코포레이션	대사 질환의 치료용 화합물
ES2530235T3 (es) *	2003-02-13	2015-02-27	Wellstat Therapeutics Corporation	Compuestos para el tratamiento de trastornos metabólicos
KR101127390B1 (ko) *	2003-04-15	2012-03-23	웰스태트 테러퓨틱스 코포레이션	대사 질환의 치료용 화합물
EP1618086B1 (de) *	2003-04-22	2009-12-02	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
WO2004098496A2 (en) *	2003-04-30	2004-11-18	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
NZ545268A (en) *	2003-08-20	2009-05-31	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders
WO2006127133A2 (en) *	2005-04-01	2006-11-30	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
UA95613C2 (ru) *	2005-11-09	2011-08-25	Уеллстат Терепьютикс Корпорейшн	Соединения для лечения расстройсв метаболизма
KR20080086523A (ko) *	2006-01-25	2008-09-25	웰스태트 테러퓨틱스 코포레이션	물질대사 장애의 치료용 화합물
CN101374414A (zh) *	2006-01-25	2009-02-25	维尔斯达医疗公司	用于治疗代谢紊乱的化合物
WO2007087505A2 (en) *	2006-01-25	2007-08-02	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
CN101378740A (zh) *	2006-02-02	2009-03-04	维尔斯达医疗公司	用于治疗代谢紊乱的化合物
CA2637884A1 (en) *	2006-02-13	2007-08-23	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
US20100227901A1 (en) *	2006-02-28	2010-09-09	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
MX2008012506A (es) *	2006-03-31	2008-10-14	Wellstat Therapeutics Corp	Tratamiento de combinacion de trastornos metabolicos.
KR20090010035A (ko) *	2006-05-18	2009-01-28	웰스태트 테러퓨틱스 코포레이션	물질대사 장애의 치료용 화합물
JP5252585B2 (ja) *	2006-06-09	2013-07-31	ウェルスタットセラピューティクスコーポレイション	代謝障害の治療のための化合物
EP2056673A4 (de) *	2006-08-17	2010-06-16	Wellstat Therapeutics Corp	Kombinationsbehandlung für stoffwechselerkrankungen
JP5496913B2 (ja) *	2008-01-15	2014-05-21	ウェルスタットセラピューティクスコーポレイション	代謝異常の治療のための化合物
KR101677944B1 (ko)	2008-03-13	2016-11-21	웰스태트 테러퓨틱스 코포레이션	화합물 및 요산을 감소시키기 위한 방법
EP2285777B1 (de) *	2008-05-05	2016-09-07	Wellstat Therapeutics Corporation	Synthese von 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutansäure
WO2010053910A1 (en)	2008-11-04	2010-05-14	Wellstat Therapeutics Corporation	Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
US8337835B2 (en) *	2009-04-10	2012-12-25	Washington University	Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE949521C (de) *	1955-01-09	1956-09-20	Merck Ag E	Lichtschutzmittel
FI66005C (fi) *	1975-02-04	1984-08-10	Fujisawa Pharmaceutical Co	Foerfarande foer framstaellning av antibakteriellt verkande 7-alfa alfa-disubstituerad-acetamido)-3-substituerad-3-cefe m--karboxylsyras syn-isomer
AU543804B2 (en) *	1980-10-31	1985-05-02	Takeda Chemical Industries Ltd.	Amides having bicyclic substituents on nitrogen
US4474809A (en)	1983-01-20	1984-10-02	American Cyanamid Company	Arylglyoxals
JPS6261587A (ja) *	1985-09-12	1987-03-18	Ajinomoto Co Inc	光学活性（ｒ）−ヒドロキシマンデル酸エステル中間体の製造法
DE3806874A1 (de) *	1988-03-03	1989-09-14	Basf Ag	Substituierte hydrazone und diese enthaltende fungizide
JP2533651B2 (ja) *	1988-09-13	1996-09-11	財団法人相模中央化学研究所	２―オキソ―３―芳香族カルボン酸誘導体の製造方法
EP0512352B1 (de) *	1991-05-09	1996-03-27	F. Hoffmann-La Roche Ag	Substituierte Carbonsäurederivate
US5589492A (en) *	1992-04-10	1996-12-31	Smithkline Beecham Plc	Heterocyclic compounds and their use in the treatment of Type-II diabetes
IL111613A0 (en) *	1993-11-12	1995-01-24	Rhone Poulenc Rorer Ltd	Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US5453443A (en)	1994-07-20	1995-09-26	Merck Frosst Canada, Inc.	Bis(aryloxy)alkanes as inhibitors of phospholipase A2 enzymes
US5665387A (en)	1994-09-01	1997-09-09	K.U. Leuven Research & Development	Methods and compositions for primary and secondary prevention of autoimmune diabetes
WO1999011255A1 (en) *	1997-08-28	1999-03-11	Ono Pharmaceutical Co., Ltd.	Peroxisome proliferator-activated receptor controllers
AU4543899A (en)	1998-06-08	1999-12-30	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
AU7313200A (en) *	1999-09-16	2001-04-17	Takeda Chemical Industries Ltd.	Alpha-keto esters and processes for the preparation thereof
GB9927056D0 (en) *	1999-11-17	2000-01-12	Karobio Ab	Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
KR100965201B1 (ko) *	2001-06-12	2010-06-24	웰스테트 테라퓨틱스 코포레이션	대사 질환의 치료용 화합물
AU2003286728A1 (en)	2002-11-01	2004-06-07	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
ES2530235T3 (es)	2003-02-13	2015-02-27	Wellstat Therapeutics Corporation	Compuestos para el tratamiento de trastornos metabólicos
KR101127390B1 (ko)	2003-04-15	2012-03-23	웰스태트 테러퓨틱스 코포레이션	대사 질환의 치료용 화합물
EP1618086B1 (de)	2003-04-22	2009-12-02	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
WO2004098496A2 (en) *	2003-04-30	2004-11-18	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
NZ545268A (en) *	2003-08-20	2009-05-31	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) *	2006-01-25	2007-08-02	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
KR20080086523A (ko) *	2006-01-25	2008-09-25	웰스태트 테러퓨틱스 코포레이션	물질대사 장애의 치료용 화합물
CN101374414A (zh) *	2006-01-25	2009-02-25	维尔斯达医疗公司	用于治疗代谢紊乱的化合物

2004
- 2004-04-20 WO PCT/US2004/012141 patent/WO2004098496A2/en not_active Ceased
- 2004-04-20 EP EP04750363A patent/EP1617835B1/de not_active Expired - Lifetime
- 2004-04-20 CN CNB2004800115527A patent/CN100348186C/zh not_active Expired - Fee Related
- 2004-04-20 AT AT04750363T patent/ATE526018T1/de not_active IP Right Cessation
- 2004-04-20 JP JP2006513150A patent/JP4837557B2/ja not_active Expired - Fee Related
- 2004-04-20 NZ NZ543789A patent/NZ543789A/en not_active IP Right Cessation
- 2004-04-20 MX MXPA05011592A patent/MXPA05011592A/es active IP Right Grant
- 2004-04-20 KR KR1020057020647A patent/KR101192272B1/ko not_active Expired - Fee Related
- 2004-04-20 US US10/554,586 patent/US7442796B2/en not_active Expired - Lifetime
- 2004-04-20 CA CA2522738A patent/CA2522738C/en not_active Expired - Fee Related
- 2004-04-20 AU AU2004237602A patent/AU2004237602B2/en not_active Ceased
2005
- 2005-10-27 IL IL171638A patent/IL171638A/en not_active IP Right Cessation
2008
- 2008-09-11 US US12/208,877 patent/US7749990B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1780614A (zh)	2006-05-31
WO2004098496A3 (en)	2005-03-31
KR20060006075A (ko)	2006-01-18
WO2004098496A2 (en)	2004-11-18
EP1617835A2 (de)	2006-01-25
AU2004237602B2 (en)	2009-05-28
CA2522738A1 (en)	2004-11-18
AU2004237602A1 (en)	2004-11-18
US7749990B2 (en)	2010-07-06
CA2522738C (en)	2011-11-08
IL171638A (en)	2011-06-30
US20090005451A1 (en)	2009-01-01
EP1617835A4 (de)	2009-11-18
JP2006525331A (ja)	2006-11-09
US7442796B2 (en)	2008-10-28
MXPA05011592A (es)	2005-12-15
NZ543789A (en)	2008-03-28
HK1083460A1 (en)	2006-07-07
KR101192272B1 (ko)	2012-10-17
US20070173544A1 (en)	2007-07-26
EP1617835B1 (de)	2011-09-28
JP4837557B2 (ja)	2011-12-14
CN100348186C (zh)	2007-11-14

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1111310T1 (el)	2015-08-05	Ενωσεις για την αγωγη μεταβολικων διαταραχων
ATE530066T1 (de)	2011-11-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2004073611A3 (en)	2004-11-25	Compounds for the treatment of metabolic disorders
EP1617835A4 (de)	2009-11-18	Verbindungen zur behandlung von stoffwechselstörungen
ATE450496T1 (de)	2009-12-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2007087505A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
UA95613C2 (ru)	2011-08-25	Соединения для лечения расстройсв метаболизма
WO2007095462A3 (en)	2008-05-02	Compounds for the treatment of metabolic disorders
WO2005105732A8 (en)	2007-04-19	Substituted methyl aryl or heteroaryl amide compounds
NO20003399D0 (no)	2000-06-29	<Alfa>-amionoamidderivater som er nyttige som smertestillende midler
TW200604175A (en)	2006-02-01	Ortho substituted aryl or heteroaryl amide compounds
UA88772C2 (ru)	2009-11-25	Соединения для лечения расстройств метаболизма
ATE540675T1 (de)	2012-01-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2007087504A3 (en)	2007-11-15	Compounds for the treatment of metabolic disorders
WO2007092729A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
MXPA06000651A (es)	2006-03-30	Uso de derivados de indazol para el tratamiento de dolor neuropatico.